[1] Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC). Retrieved February 11, 2025, from https://www.businesswire.com/news/home/2025021018406...
晚期癌症OS和PFS几乎翻倍,重磅ADC/Keytruda组合疗法再获批准 1.默沙东宣布欧盟委员会已批准PD-1抑制剂Keytruda与抗体偶联药物Padcev联用,作为一线治疗不可切除或转移性尿路上皮癌成人患者的治疗方案。 2.该批准决定是在欧洲肿瘤内科学会(ESMO)和欧洲泌尿外科协会(EAU)临床指南建议后做出的。 3.临床3期试验KEYNOTE-...
[3]Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol. 2020;38(21):2369-2379. [4]Owonikoko TK, Park K, Govin...
[4]Peters S, Pujol JL, Dafni U, et al. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 S...
[3] Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer 2023 Jul 06;22(1)[4] Decision of the commissioner. Proposal to withdraw approval for the breast cancer indication for AVASTIN (Bevacizumab). FDA. 2011 [5] Shun Lu, et al. 2022 ESMO IO....
3月7日,国际顶尖期刊《新英格兰医学杂志》发表了一篇名为“Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer ”的研究论文,此论文表明了一项ADC/Keytruda组合疗法III期结果: Padcev联用Keytruda一线治疗la/mUC患者的生存结局明显优于化疗,安全性结果与先前报告的一致,未发现新的安全性问题...
参考文献 Provencio M, Serna R, Nadal E, et al. Progression free survival and overall survival in NADIM II study. Presented at 2022 World Conference on Lung Cancer; August 6-9, 2022; Vienna, Austria; abstract PL03.12....
研究的主要终点为无进展生存期(PFS),次要终点包括客观缓解率(ORR)、总生存期(OS)和安全性。截至2024年4月22日,研究的中位随访时间12.2个月(95%CI,10.9-13.6);中位PFS为13.99个月(95%CI为 11.93-未达〔NR〕);中位OS 尚未成熟;患者12个月的PFS率和OS率分别为62.1%和86.2%。PD-L1阳性肿瘤患者(TPS≥5%:...
PFS 无进展生存期：Progression Free Survival 定义：”the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse” ；指的是疾病经过治疗后，没有进一步恶化的生存期，结局指标是 发生恶化或 死亡 优点...
定义:”the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse” ;指的是疾病经过治疗后,没有进一步恶化的生存期,结局指标是 发生恶化或 死亡 优点:增加了发生恶化这一结局指标节点,随访时间短一些,对应的改善...